Reading — Test 27

Reading passage

The Evolution and Spread of Bacterial Resistance The discovery of antibiotics in the twentieth century transformed medicine, converting once-lethal bacterial infections into treatable conditions. Yet the very success of these drugs set into motion an evolutionary countermeasure among the microorganisms they were designed to eliminate. Bacterial resistance, the capacity of a microbial population to survive exposure to concentrations of an antibiotic that would ordinarily kill or inhibit it, is not a modern anomaly but an ancient biological phenomenon. Genes conferring resistance have been identified in bacteria isolated from permafrost sediments tens of thousands of years old, long predating the human manufacture of antibiotics. What has changed is not the existence of resistance mechanisms but the intensity of the selective pressure acting upon them, a pressure driven overwhelmingly by widespread human use of antimicrobial compounds in medicine and agriculture. Resistance arises through several distinct molecular strategies, and a single bacterial species may employ more than one simultaneously. Some bacteria produce enzymes that chemically degrade an antibiotic before it can reach its target; the beta-lactamases that break down penicillin-class drugs are a well-documented example. Others modify the cellular structure that an antibiotic would normally bind to, so that the drug can no longer attach and exert its effect, a strategy seen in bacteria that alter their ribosomal proteins to evade drugs interfering with protein synthesis. Still other bacteria develop efflux pumps, specialized proteins embedded in the cell membrane that actively expel antibiotic molecules before they can accumulate to a harmful concentration. These mechanisms typically originate from random mutations in the bacterial genome or from the acquisition of resistance genes carried on plasmids, small circular pieces of DNA that exist independently of the main bacterial chromosome and can be transferred between cells, even across different species, through a process called horizontal gene transfer. The mechanism by which resistance spreads through a population illustrates a fundamental principle of natural selection operating on a compressed timescale. When a population of bacteria is exposed to an antibiotic, the overwhelming majority of cells, lacking any protective mutation, are killed or fail to reproduce. A small subset, however, may already carry a mutation or acquired gene that confers some degree of protection. These survivors face little competition for nutrients once their susceptible neighbors have been eliminated, and they proliferate rapidly, passing their resistance traits to subsequent generations. Because bacteria can divide every twenty to thirty minutes under favorable conditions, a resistant subpopulation can come to dominate within remarkably few generations. Critically, the antibiotic itself does not create the resistance mutation; it merely selects for organisms that already possess it, filtering the population in favor of survivors. Human behavior has accelerated this natural process considerably. The incomplete use of prescribed antibiotic courses, in which patients halt treatment once symptoms subside rather than completing the full regimen, leaves behind precisely the hardiest bacteria, those best equipped to endure partial exposure. Agricultural practices compound the problem: for decades, low doses of antibiotics were administered to livestock not to treat illness but to promote faster growth, creating a chronic, low-level selective pressure across enormous animal populations. Because resistant bacteria do not respect species boundaries or geographic borders, strains that emerge in one context can migrate into human populations through food, water, or direct contact, and can travel internationally within hours via air travel. The clinical consequences of this trend are already measurable rather than merely theoretical. Infections once reliably treated with first-line antibiotics increasingly require second- or third-line drugs, which tend to be more expensive, less effective, or more toxic to patients. Certain bacterial strains have accumulated resistance to nearly every antibiotic class available, a condition referred to as multidrug resistance, leaving physicians with few or no reliable treatment options. Public health authorities have responded with strategies including antibiotic stewardship programs, which aim to restrict prescriptions to cases where they are clearly necessary, alongside renewed investment in the discovery of novel antimicrobial compounds. Whether these countermeasures can outpace the evolutionary ingenuity of bacterial populations remains one of the more urgent open questions in contemporary medicine.